Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies

@article{Schwartz2015HumanES,
  title={Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies},
  author={Steven D. Schwartz and Carl D. Regillo and Byron L. Lam and Dean Eliott and Philip J. Rosenfeld and Ninel Z. Gregori and Jean-Pierre Hubschman and Janet L. Davis and Gad Heilwell and Marc J. Spirn and Joseph I. Maguire and Roger Gay and Jane Bateman and Rosaleen M Ostrick and Debra Morris and Matthew J. Vincent and Eddy Anglade and Lucian V. Del Priore and Robert Lanza},
  journal={The Lancet},
  year={2015},
  volume={385},
  pages={509-516}
}

Figures from this paper

Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration

Visual and physiological testing indicated limited functional improvement, albeit to different degrees between patients, and some promising early results concerning the use of transplanted hESC-RPE cells to alleviate wet-AMD are provided.

Human embryonic stem cells for retinal repair : preclinical in vitro and in vivo studies for the treatment of age-related macular degeneration with human embryonic stem cell-derived retinal pigment epithelial cells

Evidence is shown that allogeneic replacement therapy using subretinal injection of hESC-RPE in suspension can be a successful treatment if (i) the derived cells retain native RPE cell properties; (ii) the cells are transplanted early enough so theSubretinal milieu supports their integration; and (iii) the Cells can be engineered so that they can evade the host immune system and consequent graft rejection.

Human embryonic stem cell-derived retinal pigment epithelial cell transplantation for retinal degeneration

Promising results suggest that hESC-derived RPE cells could represent a novel treatment paradigm for retinal degenerations hallmarked by tissue loss or dysfunction.

Stem Cell Treatment for Age-Related Macular Degeneration: the Challenges.

The RPE rip scenario perhaps provides the ideal scenario for RPE replacement using stem cells as a mechanism of preventing photoreceptor loss, and the extent to which the promise of stem cell treatment for AMD will be fulfilled is discussed.

Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration

This work supports the feasibility and safety of hESC-RPE patch transplantation as a regenerative strategy for AMD and presents the preclinical surgical, cell safety and tumorigenicity studies leading to trial approval.

Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in macular degeneration

  • T. G. Qiu
  • Biology, Medicine
    npj Regenerative Medicine
  • 2019
This project marks the first milestone in overcoming ethical hurdles and oncogenic safety concerns associated with the use of an embryonic stem cell-derived line, and aims to draw attention to the key technical challenges pertinent to the generation of a biologically competent hESC-RPE cell line.

A Preclinical Safety Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells for Macular Degeneration.

It is concluded that transplanted CR-4 hES-derived RPE cells are well tolerated in immunosuppressed healthy and dystrophic murine retinas in age-related macular degeneration.
...

References

SHOWING 1-10 OF 43 REFERENCES

Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats.

Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies and batches of RPE derived from NIH-approved hES cells were tested and shown capable of extensive photoreceptor rescue in an animal model of retinal disease.

Embryonic stem cells as a treatment for macular degeneration

The pathophysiologic case for RPE transplantation with stem cell (SC)-derived tissue is presented, a review of the preclinical data substantiating the hypothesis and the initial clinical trials safety data from early human trials are reviewed.

Long‐Term Safety and Function of RPE from Human Embryonic Stem Cells in Preclinical Models of Macular Degeneration

Long‐term data showed no gross or microscopic evidence of teratoma/tumor formation after subretinal hESC‐RPE transplantation, suggesting that hESCs could serve as a potentially safe and inexhaustible source of RPE for the efficacious treatment of a range of retinal degenerative diseases.

Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial.

Evidence is provided that autologous transplantation of RPE is a beneficial supplement to membrane excision alone in patients with fCNV in age-related macular degeneration and may be regarded as a reasonable treatment option.

Iris pigment epithelial cell translocation in exudative age-related macular degeneration

Preliminary data suggests that IPE translocation in submacular surgery for ARMD can preserve but not improve preoperative visual acuity over 6 months, and functional results are promising compared toSubmacular membrane extraction alone and RPE transplantation.

Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization

Human fetal RPE transplants survive well in the macula for as long as 3 months and are capable of growing to cover epithelial defects caused by removal of subretinal neovascular membranes.